PCOS Is Now PMOS: What the Biggest Name Change in Women’s Health Means for Your Care
Just Announced — May 12, 2026
After 14 years of global research and 22,000+ survey responses from clinicians, researchers, and patients, Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The landmark consensus was published in The Lancet and presented at the European Congress of Endocrinology in Prague. The two names will remain interchangeable during a three-year transition period.
If you’ve been living with PCOS — now PMOS — you’ve probably felt the disconnect between your symptoms and your diagnosis for years. You were told you have “ovarian cysts.” But your biggest struggles are weight that won’t budge, insulin resistance, brain fog, anxiety, acne, hair loss, irregular periods, and fatigue that no amount of sleep fixes. None of that sounds like an ovary problem.
That’s because it isn’t. And that’s exactly why the name changed.
At Refine by Tulsi, we’ve been treating PMOS as a multisystem metabolic and hormonal condition long before the name caught up. Our physician-led approach — combining bioidentical hormone optimization, GLP-1 therapy, targeted peptides, and concierge medical oversight — addresses every dimension of this condition. Not just the ovaries. The whole woman.
This guide explains what changed, why it matters, and how we treat PMOS at our Lincoln Park and Logan Square locations in Chicago.
What Changed — and Why It Took 14 Years
The old name — Polycystic Ovary Syndrome — was based on a 1935 observation by two Chicago surgeons who described enlarged ovaries containing multiple small structures they called “cysts.” We now know those aren’t cysts at all — they’re immature ovarian follicles (eggs that stopped developing). Many women with the condition don’t even show these follicles on ultrasound.
The problem with “PCOS” went far beyond semantics:
- It implied the ovaries were the problem — leading to decades of care siloed in gynecology when the condition actually involves the endocrine, metabolic, cardiovascular, dermatologic, and psychological systems
- It delayed diagnosis — women without visible “polycystic ovaries” on ultrasound were told they didn’t have PCOS, even when they had every other symptom
- It fragmented care — patients bounced between gynecologists, endocrinologists, dermatologists, and psychiatrists because no single specialty “owned” a condition named after ovarian cysts
- It created stigma — the word “syndrome” paired with “polycystic” made women feel like something was fundamentally wrong with their reproductive organs, when the reality is a whole-body hormonal and metabolic condition
- It limited research funding — framing PCOS as a gynecological condition reduced its priority in metabolic, cardiovascular, and endocrine research
The new name — Polyendocrine Metabolic Ovarian Syndrome (PMOS) — directly addresses these failures by:
- Polyendocrine — acknowledging that multiple hormonal systems are involved (insulin, androgens, cortisol, thyroid, and more)
- Metabolic — recognizing the central role of insulin resistance, metabolic dysfunction, and cardiovascular risk
- Ovarian — maintaining the reproductive connection without reducing the condition to “cysts”
- Removing “polycystic” — eliminating the misleading reference to cysts that don’t exist as traditionally understood
What PMOS Actually Is: A Multisystem Condition
PMOS affects approximately 1 in 8 women — more than 170 million worldwide. Understanding it as a multisystem condition changes how you think about treatment.
Endocrine Disruption
Elevated androgens (testosterone, DHEA-S) drive acne, excess facial/body hair, scalp hair thinning, and irregular ovulation. But it’s not just androgens — thyroid dysfunction, cortisol dysregulation, and impaired gonadotropin signaling are all part of the picture.
Metabolic Dysfunction
Up to 70% of women with PMOS have insulin resistance — even those at a “normal” weight. This drives stubborn weight gain (particularly visceral fat), increases type 2 diabetes risk 4–8x, and elevates cardiovascular disease risk. Insulin resistance is often the engine of the entire condition.
Reproductive Impact
Irregular or absent periods, difficulty with ovulation, and fertility challenges remain significant concerns. But the new name correctly positions these as one manifestation of a broader hormonal imbalance — not the defining feature.
Skin & Hair Changes
Androgen-driven acne, hirsutism (excess body hair), and androgenic alopecia (hair thinning) are among the most distressing symptoms. Microneedling, chemical peels, and PRF therapy address the skin manifestations while medical treatment targets the hormonal root cause.
Mental Health
Depression, anxiety, and disordered eating are significantly more common in women with PMOS — driven by both hormonal imbalance and the psychological weight of living with a misunderstood, poorly named condition. The rename itself is a step toward reducing this burden.
Long-Term Health Risks
Women with PMOS face elevated lifetime risk of type 2 diabetes, cardiovascular disease, endometrial cancer, sleep apnea, and non-alcoholic fatty liver disease. This is why PMOS requires ongoing physician-led medical oversight — not just symptom management.
How We Treat PMOS at Refine by Tulsi
Because PMOS is a multisystem condition, it requires a multisystem approach. At Refine by Tulsi, we don’t treat one symptom at a time — we build a comprehensive protocol that addresses the metabolic, hormonal, aesthetic, and psychological dimensions simultaneously.
Our Approach: Six Pillars of PMOS Management
Each pillar targets a different dimension of the condition. Most patients benefit from 2–4 of these working together.
GLP-1 Therapy
Semaglutide and Tirzepatide are GLP-1 receptor agonists that reduce insulin resistance, regulate blood sugar, suppress appetite, and promote sustainable fat loss — targeting the metabolic engine driving most PMOS symptoms.
Hormone Optimization
BHRT and targeted hormonal management to address androgen excess, optimize progesterone and estrogen balance, support thyroid function, and regulate cortisol — the polyendocrine core of PMOS.
Peptide Therapy
Targeted peptides that address the downstream effects of PMOS — systemic inflammation (BPC-157), growth hormone decline (CJC/Ipamorelin), collagen loss and skin quality (GHK-Cu), and cognitive function (Selank).
Aesthetic Treatment
Medical-grade treatments for PMOS-driven acne, acne scarring, hyperpigmentation, and hair thinning — addressing the visible symptoms that affect confidence while the medical protocol works on the root cause.
IV Therapy & Nutrient Optimization
Women with PMOS commonly have depleted nutrient stores — particularly vitamin D, B12, magnesium, and inositol. IV therapy restores these directly, bypassing compromised gut absorption and supporting metabolic function.
Refine Her Program
Our membership-based women’s wellness program brings all of the above together under continuous physician oversight — with advanced diagnostics, personalized protocols, regular lab monitoring, and a community of women navigating the same challenges.
PMOS requires a physician who understands all of its dimensions. Book a consultation at refinebytulsi.com/book and we’ll build a protocol that addresses your specific symptom profile — metabolic, hormonal, aesthetic, and everything in between.
Why GLP-1 Therapy Is a Game-Changer for PMOS
If there’s one treatment that has fundamentally changed PMOS management in the last few years, it’s GLP-1 receptor agonist therapy.
Here’s why it matters so much for PMOS specifically:
Insulin resistance is the metabolic engine of PMOS. Elevated insulin drives the ovaries to produce excess androgens. Those androgens cause acne, hair loss, irregular periods, and weight gain. The weight gain worsens insulin resistance. The worsening insulin resistance drives more androgen production. It’s a vicious cycle — and traditional treatments (birth control pills, spironolactone, metformin) manage individual symptoms without breaking the cycle at its source.
Semaglutide and Tirzepatide break the cycle by:
- Improving insulin sensitivity — directly addressing the metabolic dysfunction at the core of PMOS
- Promoting meaningful fat loss — particularly visceral fat, which is the most metabolically active and most closely linked to insulin resistance and androgen production
- Reducing appetite and cravings — addressing the carbohydrate cravings that insulin resistance drives, making dietary changes sustainable rather than torturous
- Lowering androgen levels indirectly — as insulin improves and visceral fat decreases, androgen production often normalizes, improving acne, hair loss, and menstrual regularity without additional medications
- Reducing cardiovascular risk — GLP-1 agonists have demonstrated cardioprotective effects, which is significant given the elevated cardiovascular risk PMOS carries
At Refine by Tulsi, our medical weight loss program combines GLP-1 therapy with peptide protocols, nutritional guidance, exercise planning, and monthly weigh-ins — ensuring that weight loss preserves lean muscle and addresses the metabolic dysfunction rather than just the number on the scale.
How Peptides Support PMOS Beyond What Hormones and GLP-1 Can Do
Hormone optimization addresses the endocrine dysfunction. GLP-1 therapy addresses the metabolic engine. Peptide therapy fills the gaps that neither fully covers:
- BPC-157 for gut health and inflammation — Women with PMOS have elevated systemic inflammation and often compromised gut lining integrity. BPC-157 repairs gut mucosa, reduces inflammatory markers, and supports the gut-hormone axis that influences insulin sensitivity, mood, and immune function.
- CJC-1295/Ipamorelin for body composition — Growth hormone secretagogues support lean muscle retention during weight loss, improve fat metabolism, enhance sleep quality, and accelerate recovery — all areas where PMOS women struggle disproportionately.
- GHK-Cu for skin quality and hair — The copper peptide stimulates collagen, elastin, and glycosaminoglycan production while supporting hair follicle health. Combined with microneedling or PRP hair restoration, it addresses the dermatologic manifestations of PMOS that affect confidence most.
- Selank for brain fog and anxiety — The nootropic peptide modulates GABA and serotonin pathways, providing cognitive support and anxiety reduction that complements hormonal management. PMOS-related brain fog and mood changes often persist even after hormones are optimized — Selank targets these pathways directly.
- TB-500 for recovery — Active women with PMOS often experience slower recovery and increased joint pain related to systemic inflammation. Thymosin Beta-4 accelerates tissue repair and reduces inflammatory signaling.
What a PMOS Protocol Looks Like at Refine by Tulsi
Phase 1: Diagnosis and Baseline (Week 1–2)
Comprehensive consultation with Dr. Kotecha or Dr. Ruof. Full lab panel: complete hormones (testosterone, free testosterone, DHEA-S, estradiol, progesterone, thyroid, cortisol, SHBG), metabolic markers (fasting insulin, glucose, HbA1c, lipid panel), inflammatory markers (hs-CRP, homocysteine), and nutrient status (vitamin D, B12, ferritin, magnesium). We assess your full symptom profile across all PMOS dimensions.
Phase 2: Metabolic Foundation (Week 2–8)
If insulin resistance is present (it usually is), we start GLP-1 therapy to break the metabolic cycle. Concurrent nutritional guidance with an anti-inflammatory, lower-glycemic framework. IV nutrient therapy to restore depleted stores (vitamin D, magnesium, B12) that support metabolic function.
Phase 3: Hormonal Optimization (Week 4–12)
Once metabolic improvement is underway, we layer hormonal management — which may include bioidentical progesterone, thyroid optimization, adrenal support, and targeted anti-androgen strategies. For some patients, GLP-1-driven weight loss and insulin improvement alone normalize androgens enough that additional hormonal intervention is minimal.
Phase 4: Peptide Layering (Week 8+)
Based on remaining symptoms and lab results, we add 1–2 targeted peptides — BPC-157 for persistent inflammation and gut issues, CJC/Ipamorelin for body composition and energy, GHK-Cu for skin and hair, or Selank for cognitive support.
Phase 5: Aesthetic Integration (Ongoing)
For PMOS-driven skin concerns, we layer microneedling with PRP for acne scarring and texture, chemical peels for hyperpigmentation, laser skin rejuvenation for overall tone, and PRP hair restoration for thinning hair. These work best once the internal hormonal and metabolic environment is improving.
Ongoing: Monitoring and Adjustment
Labs repeated at 8–12 weeks. Check-ins monthly. Protocols adjusted based on objective data and subjective response. PMOS is a lifelong condition — and our Refine Her membership program provides the ongoing physician oversight, diagnostics, and treatment access that long-term management requires.
Real Patient Experiences
I was diagnosed with PCOS at 22 and spent ten years being told to “just lose weight” and take birth control. No one ever tested my insulin. Dr. Kotecha ran a full panel and my fasting insulin was through the roof. She started me on Semaglutide and within three months I’d lost 25 pounds — but more importantly, my periods came back on their own for the first time in years. The weight loss improved my insulin, which improved my hormones, which improved everything. I finally understood what was actually wrong.
My biggest PCOS struggle was my skin — cystic acne along my jaw and chin that nothing topical could fix. Dr. Ruof explained it was androgen-driven and put me on a protocol: hormone optimization to address the androgens, BPC-157 for the inflammation, and a series of microneedling with PRF for the scarring. Six months later my skin is clear. Actually clear. I stopped wearing foundation for the first time since high school.
I’m a “lean PCOS” patient — normal weight, but insulin resistant, irregular periods, terrible brain fog, and my hair was thinning. My old doctor said I didn’t fit the PCOS profile because I wasn’t overweight. Dr. Ruof listened, ran the right labs, and confirmed PMOS with elevated androgens and high fasting insulin despite my normal BMI. She started me on a low-dose GLP-1, optimized my progesterone and thyroid, and added Selank for the fog. Within two months I felt like a different person. The name change makes sense — this was never just about my ovaries.
I joined the Refine Her Thrive tier specifically for PCOS management. Having everything in one place — my hormones, my GLP-1, my peptides, my skin treatments, my labs — with one team that actually talks to each other? That’s what was missing from ten years of bouncing between specialists. For the first time, someone is looking at the whole picture. And the results show it.
What the Name Change Means for You Right Now
Practically speaking, here’s what changes — and what doesn’t:
What Changes
The understanding of the condition. PMOS is now formally recognized as a polyendocrine (multi-hormonal) and metabolic condition — not a gynecological one. This should lead to earlier diagnosis, better insurance coverage for metabolic treatments, more research funding, and care that addresses the full spectrum of symptoms.
The conversation. You can now tell your doctors, your employer, your insurance company that you have a metabolic and endocrine condition. That carries different weight than “ovarian cysts.”
What Doesn’t Change
Your body. The condition is the same. Your symptoms are the same. The treatments that work are the same. What changes is the framework — and at Refine by Tulsi, we’ve been operating within the correct framework all along.
Existing diagnoses. If you’ve been diagnosed with PCOS, you now have PMOS. Both names will be used interchangeably during a three-year transition period. No new testing is required to “convert” your diagnosis.
Frequently Asked Questions
Is PMOS a different condition than PCOS?
No — it’s the same condition with a new name that more accurately describes what’s happening in your body. Polyendocrine Metabolic Ovarian Syndrome replaces Polycystic Ovary Syndrome to reflect the multi-system hormonal and metabolic nature of the condition. Both names will be used interchangeably during a three-year transition period.
Do I need to be retested or rediagnosed?
No. If you have a PCOS diagnosis, you have PMOS. The diagnostic criteria remain the same. However, if you’ve never had a comprehensive metabolic panel (fasting insulin, HbA1c, lipids) alongside your hormonal testing, we’d strongly recommend one — many women with PCOS/PMOS have undiagnosed insulin resistance that changes the treatment approach significantly.
Can I take GLP-1 medication if I’m trying to conceive?
GLP-1 medications like Semaglutide should be discontinued at least 2 months before attempting conception. However, the metabolic improvements from GLP-1 therapy — reduced insulin resistance, weight loss, normalized androgens — often dramatically improve fertility outcomes. Many patients use GLP-1 therapy as part of their preconception optimization, then transition off before trying to conceive.
I’m not overweight — can I still have PMOS?
Absolutely. “Lean PMOS” affects approximately 20–30% of women with the condition. You can have insulin resistance, androgen excess, and every other PMOS feature at a normal BMI. The old association between PCOS and obesity was one of the most harmful misconceptions — it led to countless lean women being dismissed by doctors who equated the condition with being overweight.
Will insurance cover GLP-1 therapy for PMOS?
Coverage varies by plan. GLP-1 medications are currently FDA-approved for type 2 diabetes and obesity — both of which frequently co-occur with PMOS. The name change to PMOS may help improve insurance framing over time by positioning the condition within metabolic medicine rather than gynecology. We can help you navigate coverage options during your consultation.
What’s the difference between your approach and just going to a gynecologist?
A gynecologist addresses the reproductive dimension of PMOS — periods, ovulation, fertility. At Refine by Tulsi, we address all dimensions: metabolic (GLP-1, weight management), endocrine (hormone optimization), inflammatory (peptides, IV therapy), aesthetic (skin treatments, hair restoration), and psychological (through better clinical outcomes and the Refine Her community). One team, one plan, all under physician oversight.
How much does PMOS treatment cost?
It depends on your protocol. Individual treatments (GLP-1 therapy, peptides, aesthetic sessions) can be booked à la carte. For comprehensive PMOS management with ongoing physician oversight, diagnostics, and integrated treatment, our Refine Her program starts at $599/month (Balance tier) or $1,299/month (Thrive tier with advanced peptides, regenerative therapies, and quarterly rejuvenation treatments).
The Bottom Line
The rename from PCOS to PMOS isn’t just semantics — it’s a formal recognition of what women with this condition have known in their bodies for years: this is not an ovary problem. It’s a whole-body hormonal and metabolic condition that deserves whole-body care.
At Refine by Tulsi, we’ve been treating it that way all along — with GLP-1 therapy for insulin resistance and weight, bioidentical hormones for endocrine balance, targeted peptides for inflammation and recovery, medical-grade aesthetics for skin and hair, IV nutrient therapy for cellular support, and physician-led oversight that ties it all together.
The name finally caught up to the science. The science has been here all along.
Ready to Treat PMOS the Way It Deserves to Be Treated?
Schedule your PMOS consultation with Dr. Kotecha or Dr. Ruof. We’ll run the full panel, identify your primary drivers, and build a comprehensive protocol that addresses every dimension — metabolic, hormonal, aesthetic, and beyond.
About Dr. Tulsi Kotecha
Dr. Tulsi Kotecha is the founder and medical director of Refine by Tulsi, a physician-led aesthetic and wellness practice with locations in Lincoln Park and Logan Square, Chicago. She specializes in integrative longevity medicine, combining hormone optimization, peptide therapy, metabolic medicine, and regenerative aesthetics.
Dr. Kotecha designed the Refine Her program to give women with complex conditions like PMOS the comprehensive, physician-led care they deserve — treating the whole woman, not just one symptom at a time. Learn more about Dr. Kotecha.
This article is for educational purposes and does not constitute medical advice. PMOS (formerly PCOS) treatment should be administered under the guidance of a qualified physician. Individual results may vary. The PCOS-to-PMOS name change was published in The Lancet on May 12, 2026.
